Product Information
BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE is a generic product labeled by Aurolife Pharma LLC, priced at $1.9312 per EA under NDC 13107007501. Its NADAC has been published 396 times since Mar 6, 2019.
FDA first approved this application on Sep 26, 2018. Its Orange Book therapeutic-equivalence code is AA.
BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE
Butalbital, Acetaminophen and CaffeineStrength
325; 50; 40 mg/1; mg/1; mg/1
Manufacturer
Aurolife Pharma LLCNDC
13107007501
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ACETAMINOPHEN; BUTALBITAL; CAFFEINEApproval Type
Generic (ANDA)
FDA Application
ANDA204733FDA Approved
9/26/2018
TE Code
AA
On Market Since
4/26/2017
Pharmacological Classes
Price Statistics
The NADAC for BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE has been published 396 times since Mar 6, 2019, and over the history we have for it it has declined 50.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.9312 per EA |
|---|---|
| All-time high | $3.8847 (May 15, 2019) |
| All-time low | $1.6931 (Jun 17, 2026) |
| 52-week high | $2.3000 |
| 52-week low | $1.6931 |
| Median price | $2.7477 |
| Average price | $2.8418 |
| Largest weekly change | +37.8% (Jun 19, 2024) |
| Weeks tracked | 396 |
| Tracking since | Mar 6, 2019 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Butalbital, Acetaminophen and Caffeine market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aurolife Pharma LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Butalbital, Acetaminophen and Caffeine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Barbiturate class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE, manufactured by Aurolife Pharma LLC, is $1.9312 per EA (NDC 13107007501), effective Sep 30, 2026.
How has the price of BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE has declined 50.3%. It has been tracked across 396 weekly CMS publications since Mar 6, 2019.
What are the highest and lowest recorded NADAC prices for BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE?
Since Mar 6, 2019, the NADAC for BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE has ranged from a low of $1.6931 (Jun 17, 2026) to a high of $3.8847 (May 15, 2019), with a median of $2.7477 per EA.
Are there cheaper alternatives to BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE?
BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE (NDC 13107007501) is labeled by Aurolife Pharma LLC, and CMS classifies it as a generic product.